Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients

Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients

Abstract Background This study aimed to evaluate possible treatment strategies for patients with de novo T790M mutation‐positive (T790M+) non‐small‐cell lung cancer (NSCLC). Methods Patients diagnosed with de novo T790M+ NSCLC and treated with epidermal growth factor receptor tyrosine kinase inhibit...

Full description

Bibliographic Details
Main Authors: John Wen‐Cheng Chang, Chen‐Yang Huang, Yueh‐Fu Fang, Ching‐Fu Chang, Cheng‐Ta Yang, Chih‐Hsi Scott Kuo, Ping‐Chih Hsu, Chiao‐En Wu
Format: Article
Language:English
Published: Wiley 2022-07-01
Series:Thoracic Cancer
Subjects:
afatinib
lung cancer
osimertinib
T790M mutation
Online Access:https://doi.org/10.1111/1759-7714.14272

Internet

https://doi.org/10.1111/1759-7714.14272

Similar Items